A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

The sea lions will likely join nearby communities in Oceanside or La Jolla, or swim up north to other populations off.

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Sarclisa was administered subcutaneously via an on-body delivery system (OBDS) in the investigational, randomized, open-label clinical trial and demonstrated that compared with IV treatment, patients ...

Opens in a new tab or window Event-free survival in high-risk non-muscle invasive bladder cancer improved significantly with the addition of the subcutaneously administered PD-1 inhibitor ...

The Food and Drug Administration (FDA): a federal agency that protects the public's health. This approval brings a subcutaneously administered PD1 inhibitor to the market, and it could be significant ...